Portfolio
Our Portfolio is under Intellectual Property, for the use of potential drug candidates directed to a wide range of cancer indications.
Scientific Platform
Our ongoing research is shedding light into several biomarkers that may be good predictors of clinical response to immunotherapy.
We are capable of developing a Scientific Platform that will serve physicians to diagnose in a truly personalized way.